
Yuvezzi’s Health Canada submission leads this week’s recap, plus AI front desks, the EMERALD trial, and Alberta’s scope expansion.
Give us your opinion on our latest poll, and see what your colleagues are saying. You can see the results of our previous surveys here as well.





